TIDMIXI

RNS Number : 2029Z

IXICO plc

13 March 2017

13 March 2017

IXICO plc

("IXICO" or the "Company")

IXICO signs US$1.5m contract

New contract with an existing top 10 pharma customer

Endorsement of IXICO's expertise in brain diseases and the value to pharma of its innovative technology for image analysis

IXICO, the brain health company, today announces that it has signed a new contract worth US$1.5m for its Imaging Clinical Trial Technologies and Services with an existing customer which is a top 10 pharmaceutical company.

The contract is for the supply of services to a Phase IIb clinical trial of patients in the early stages of Progressive Supranuclear Palsy ("PSP"), a Parkinson's-like neurodegenerative condition caused by the premature loss of nerve cells in certain parts of the brain.

IXICO will collect, manage and analyse MRI scans acquired at over 90 international specialist imaging centres utilising its proprietary TrialTracker(TM) platform. This data analytics technology has been specifically modified for quantifying drug effects in PSP patients. This current study is expected to complete in 2020 and there is potential for the scope to be extended further.

Giulio Cerroni, Chief Executive of IXICO, commented: "We are pleased to announce the signing of a further contract with a top pharma company highlighting our leading position in providing proprietary digital technologies and services for the analysis of big data sets from clinical trials, especially in the area of neurodegenerative disease. This contract further demonstrates existing customers' endorsement of IXICO's ability to provide compliant delivery of quality data and trustworthy results, and cements our position as a valued partner to the pharmaceutical industry in the drug development process."

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive            Tel: +44 20 
  Officer                                    3763 7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield            7408 4090 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan/Matthew Moss

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy is a Parkinson's-like neurological condition caused by the premature loss of nerve cells in certain parts of the brain. Over time this leads to difficulties with balance, movement, vision, speech and swallowing. Research suggests around 20,000 people suffer with PSP in the US alone.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTMMGMFNGLGNZM

(END) Dow Jones Newswires

March 13, 2017 03:00 ET (07:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ixico Charts.
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ixico Charts.